Lateral Epicondylitis Treatment Market Set for Significant Growth
The global market for lateral epicondylitis treatments is expected to grow significantly by 2030, reaching a valuation of $2.98 billion and a compound annual growth rate (CAGR) of 4.9%. This expansion is driven by factors such as the adoption of minimally invasive procedures, the aging working population, and the integration of digital physiotherapy platforms.
Key trends influencing the market include a preference for non-surgical treatments, expanded use of physical therapy, increased implementation of image-guided injections, growth in outpatient orthopedic services, and a more holistic approach combining rehabilitation with pain management.
The market is shaped by several influential organizations, including Merck & Co. Inc., 3M Company, Mayo Foundation for Medical Education and Research (MFMER), Cleveland Clinic, and others. A notable recent development was the partnership between TendoNova and AcCELLerated Biologics LLC in March 2023 to blend innovative micro-invasive tendon treatment devices with biologic therapies.
Innovative therapies are becoming a focal point for market players seeking to broaden treatment options. The use of plasma therapies, such as platelet-rich plasma (PRP) therapy, is gaining attention due to its non-surgical alternatives for orthopedic patients.